Vancouver, British Columbia – TheNewswire – September 23, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary Trip Pharma, a Psychedelic Development and Wellness Company and operator of LeichtMind multidisciplinary clinics, has partnered with MindBio Therapeutics to launch MindBio’s microdosing trials in Canada.

MindBio Therapeutics, a 100% owned subsidiary of Blackhawk, has signed an agreement with Trip Pharma’s LeichtMind clinic to develop protocols necessary to launch clinical trials in Canada. LeichtMind has the appropriate infrastructure, detailed understanding of regulatory requirements, and highly qualified personnel to assist MindBio Therapeutics to fast track its activities in Canada. This is a significant agreement for Blackhawk that will bring the skills, expertise and training programs related to “assisted psychedelic therapies” to the Canadian landscape and connect Dr Krista Leicht to the MindBio management team.

MindBio Therapeutics is a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine. It is one of a small group of companies in the world conducting advanced clinical trials in psychedelic medicine. It recently announced it will facilitate research and drug development “as a service” to the pharmaceutical industry to potential clients in the United States and Canada that will help accelerate the development of any substance or compound in the psychedelic sector. LeichtMind becomes another pillar for MindBio to build a global platform for delivering innovative and effective mental health treatments.

“The partnership between MindBio, Trip Pharma and LeichtMind provides the first of many opportunities generating new sources of revenue opportunities and establishing a global footprint of solutions for a range of medical health conditions. We look forward to updating our shareholders with our progress over the coming weeks and months ahead” said Frederick Pels, CEO of Blackhawk Growth.

Dr. Krista Leicht

Dr. Leicht is a Canadian-trained and Alberta-licensed medical doctor and psychiatrist, who brings over 20 years of clinical experience to the team. She has divided her time in a busy practice between inpatient and outpatient care, treating both the general adult psychiatry population and specializing in addressing the complex needs of developmentally handicapped individuals. Dr. Leicht maintains a hospital practice at Alberta Hospital Edmonton and sees outpatients in a South Edmonton clinic. She continues to teach medical students, residents and provides further education to family-practice colleagues. Dr. Leicht’s goal in clinical practice and in her own life has always been to go beyond — to provide unique and innovative treatments that better enrich the lives of patients is her mission.

MindBio Therapeutics Management Team:

Dr. Zena Burgess, PhD. FAICD,FAPS – Non-Executive Director

Zena serves as the Chief Executive Officer of the Australian Psychologists Society and formerly as Chief Executive of the Royal Australian College of General Practitioners. She is a member of the international advisory board of Connext2MyDoctor and the telehealth influencers alliance. She is also a director of the Australian Patients Association and Chair of the board subcommittee on governance and risk of the Victorian Farmers Federation. Zena has substantial experience serving on boards of government entities. She holds a PhD in psychology from the Australian Catholic University and a Master of Business Administration from Monash University and a Master of Education from La Trobe University. She has a wealth of experience in health changes and strategic advocacy to governments.

Gavin Upiter – Chairman

Gavin has over 25 years of experience leading companies in the pharmaceutical sector.  Engineering qualified, prior to founding Generic Health, a leading generic pharmaceutical company which was sold to Lupin Pharmaceuticals, (NSE: LUPIN), Gavin started his executive career at Bristol Myers Squibb.  He was Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX) and Executive Director of Slade Health, Australia’s leading hospital pharmacy chain.  Gavin founded Directo, Australia’s first online pharmaceutical B2B marketplace for pharmacies and suppliers.

Justin Hanka – Co-Founder & Director

Justin Hanka works in investment banking and financing of mergers and acquisitions and capital markets transactions.  He is Non-Executive Director of EonX (CSE:EONX), a financial technology company, Non-Executive Director of Goldcar, (a Europcar Company listed on the Euronext in France), Non-Executive Director of The Digital Tribes Company, an IT digital transformation company headquartered in Sweden.  He is an experienced executive having served as Chief Operating Officer for iSelect (ASX: ISU) and having sold Helpmechoose as its CEO to Mortgage Choice (ASX:MOC).  Justin’s expertise spans the pharmaceutical and health sector including pharmaceuticals,  pharma-technologies, fin-techs, digital transformation and technology, influencer marketing, health and wellness, entertainment and ecommerce.

Colin Keating – Director

Colin is an experienced CEO and Managing Director having led publicly listed Hogg Robinson Group Australia (LSE) and BuyMyPlace (ASX), both large private technology led organisations and has also held senior global leadership positions with the likes of American Express. With over 25 years experience in both established and scale up businesses, Colin possesses a demonstrable track record in driving growth, shaping organisational culture and delivering shareholder value. His experience is broad and varied having worked across multiple industries including Financial Services & Payments, Corporate Travel, Property Tech, Health Tech, Data Management and Wealth Management. Colin also has deep experience working in, and advising, organisations on strategic initiatives such as capital raising, M&A activities, IPO’s and exit strategies. Having worked in the United Kingdom, Hong Kong and the US, Colin’s global experience will be of enormous benefit to Mind Therapeutics as the business grows both domestically and across international markets.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel  

Please join the conversation on our Blackhawk group supporter’s telegram group at and visit us online at

For further information please contact:

Frederick Pels, Chief Executive Officer


This email address is being protected from spambots. You need JavaScript enabled to view it.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.